bpc-157 compounding restrictions fda Exciting news for peptides coming out of today's committee hearing! The Pharmacy Advisory Committee voted 8-6 to recommend adding BPC- 157 to the 503A Bulks List for use in compounding for BREAKING: The FDA just reversed

BREAKING: The FDA just reversed theIR 2023 peptide ban. 12 peptides were just pulled from the Category 2 restricted list: 1. BPC 157 2. Thymosin beta 4 fragment (TB 500) 3. Epitalon 4. GHK Cu (injectable) FDA's own advisory committee voted 8 6 Thursday. BPC 157, on the compounding list now, for ulcerative colitis. FDA staff argued against it, laid out the data gaps, the whole case. Panel overruled them A step towards expanded patient access. This will allow patients to have conversations about these compounds in the clinical setting instead of resorting to a gray market without practitioner oversight or monitoring! BPC 157 approved by FDA today to add as a compounded substance : r PeptidePathways The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and 83% of peptide aware Americans want the FDA to make peptides more accessible AOL

SKU: 29987305642 · From reganhouse.co.nz